7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-06-30 2014-03-31 2013-09-30 2013-06-30 2013-03-31 2012-09-30 2012-06-30 2012-03-31 2010-12-31 2008-12-31 2008-09-30 2008-06-30 2008-03-31 2007-12-31 2007-09-30 2007-06-30 2007-03-31 2006-12-31 2006-09-30 2006-06-30 2006-03-31 2005-12-31 2005-09-30 2005-06-30 2005-03-31 
      
    		                                                                    
      cash flow from operating activities:
    		                                                                    
      net income
    		466,500,000 634,800,000 240,500,000 266,700,000 388,500,000 583,600,000 393,400,000 248,900,000 -68,300,000 593,300,000 387,600,000 549,500,000 1,134,900,000 1,058,700,000 218,500,000 -20,500,000 318,000,000 1,025,500,000 404,600,000 357,600,000 703,900,000 1,606,400,000 1,392,600,000 1,439,700,000 1,545,900,000 1,494,100,000 1,408,800,000 944,900,000 1,442,900,000 915,000,000 1,171,200,000 -166,300,000 1,226,100,000 862,800,000 747,500,000 647,900,000 1,030,200,000 1,048,400,000 969,200,000 828,708,000 1,019,493,000 924,825,000 820,174,000 723,132,000 479,728,000 487,616,000 490,670,000 426,749,000 398,399,000 387,141,000 302,366,000 897,946,179 206,654,000 206,788,000 206,628,000 163,097,000 201,150,000 119,381,000 186,140,000 131,501,000 108,556,000 156,599,000 -170,613,000 122,969,000 55,562,000 27,185,000 34,506,000 43,458,000 
      adjustments to reconcile net income to net cash flow from operating activities:
    		                                                                    
      depreciation and amortization
    		202,200,000 194,300,000 183,200,000 184,000,000 182,800,000 158,900,000 147,500,000 140,100,000 125,000,000 117,400,000 112,300,000 119,800,000 120,700,000 134,800,000 143,100,000 134,700,000 133,200,000            346,500,000 171,500,000 168,900,000    512,000,000 177,400,000 180,200,000 175,400,000 149,700,000 156,300,000 151,577,000 144,586,000 147,937,000 164,139,000 190,963,000 147,477,000 128,427,000 97,453,000 94,203,000 90,624,000 83,945,000             123,230,000 97,524,000 109,751,000 98,822,000 96,111,000 
      impairment of intangible assets
    		0   40,000,000            0 43,400,000                                                    
      excess and obsolescence charges related to inventory
    		-400,000 7,000,000 7,300,000 33,200,000 24,300,000 16,900,000 27,500,000 62,300,000 25,300,000 19,400,000 17,400,000 14,600,000 16,000,000 24,100,000 281,500,000                                                      
      amortization of acquired inventory step-up
    		61,500,000 52,500,000 51,400,000 44,900,000 50,900,000                                                                
      share-based compensation
    		75,300,000 74,900,000 81,000,000 75,100,000 72,700,000 70,600,000 72,800,000 54,900,000 62,200,000 71,500,000 75,600,000 67,200,000 63,600,000 55,700,000 67,600,000 58,800,000 55,700,000 54,100,000 70,000,000 49,000,000 33,500,000 48,100,000 67,700,000 38,400,000 45,900,000 52,300,000 45,700,000 38,500,000 37,300,000 38,300,000 43,400,000 30,600,000 30,100,000 30,300,000 37,000,000 37,000,000 33,700,000 38,800,000 45,300,000 29,863,000 37,860,000 41,614,000 52,063,000 37,516,000 46,340,000 37,464,000 30,630,000 36,757,000 27,911,000 28,071,000 32,396,000 167,691,406  36,692,000 33,118,000 34,529,000             
      contingent consideration
    		5,600,000 13,200,000 9,600,000 3,900,000        -195,400,000 -2,100,000 -4,500,000 -7,100,000 -1,600,000 -15,600,000 300,000 -33,800,000 -62,800,000 -29,000,000 10,100,000 -4,600,000 2,600,000 -57,800,000 -20,000,000 11,500,000 79,300,000                                         
      deferred income taxes
    		253,800,000 -31,300,000 -27,800,000 -58,400,000 -52,600,000 -87,000,000 39,900,000 71,900,000 -206,800,000 -106,400,000 -64,500,000 -28,800,000 -92,300,000 -48,500,000 1,000,000 323,300,000 -127,300,000 -607,800,000 -15,000,000 -62,900,000 31,700,000 143,300,000 36,900,000 38,700,000 -43,200,000 -156,400,000 228,000,000 153,100,000 12,600,000 -110,500,000 53,100,000 131,400,000 -19,200,000 -96,600,000 76,100,000 -118,200,000 -26,600,000 -39,100,000 8,900,000 40,202,000 -95,155,000 -107,386,000 16,739,000 -66,948,000 -79,558,000 -48,140,000 -51,522,000 -66,525,000 -43,027,000 -39,955,000 -3,876,000 -81,348,756 -81,958,000 -42,834,000 -21,940,000 7,183,000 -41,189,000 -22,194,000 -23,187,000 5,015,000 -26,560,000 -33,679,000 -19,566,000 -26,532,000 16,672,000 -32,651,000 -73,731,000 -25,829,000 
      (gain) loss on strategic investments
    		500,000 -7,700,000 40,900,000 78,700,000 -38,900,000 30,300,000 31,300,000 1,400,000 302,500,000 -106,400,000 79,600,000 105,600,000 -109,000,000 78,200,000 191,100,000 116,300,000 426,900,000 -154,000,000 437,600,000                                                  
      gain on sale of priority review voucher
    		   0 0                                                                
      other
    		33,300,000 9,300,000 6,700,000 64,500,000 30,100,000 39,600,000 25,400,000 49,600,000 38,100,000 29,100,000 31,400,000 60,400,000 35,600,000 68,900,000 43,300,000 1,200,000 88,600,000 40,700,000 71,700,000 21,100,000 24,800,000 39,600,000 45,700,000 -18,200,000 -3,700,000 40,400,000 50,700,000 -900,000 -110,600,000 16,300,000 26,100,000 35,200,000 53,400,000 55,400,000 18,100,000 57,800,000 13,600,000 40,000,000 -20,200,000 50,636,000 37,372,000 27,113,000 -32,921,000 7,263,000 -71,476,000 5,918,000 -9,053,000 -33,442,000 27,113,000 8,003,000 -29,073,000             1,193,000   -536,000 -1,369,000 
      changes in operating assets and liabilities, net of effects of business acquired:
    		                                                                    
      accounts receivable
    		245,400,000 10,500,000 -181,000,000 94,700,000 115,300,000 -31,400,000 43,700,000 137,800,000 -98,300,000 -55,400,000 77,200,000 -93,900,000 -42,200,000 20,200,000 -87,500,000 167,000,000 -53,700,000 174,300,000 37,200,000 138,500,000 133,100,000 -30,400,000 -238,400,000 71,200,000 500,000 133,700,000 -136,600,000 48,800,000 -66,800,000 -53,200,000 -134,000,000 -209,800,000 75,400,000 -105,500,000 -195,700,000 -3,300,000 -173,100,000 95,000,000 -160,000,000 92,608,000 -24,701,000 89,380,000 -128,287,000 8,724,000 -197,685,000 -34,172,000 -110,142,000 -75,546,000 29,244,000 78,308,000 -89,066,000 -99,154,281 37,772,000 -9,035,000 -31,599,000 -54,703,000 -12,978,000 -16,724,000 -34,357,000 -6,642,000 -18,164,000 2,036,000 -11,396,000 -9,485,000 -5,245,000 -7,635,000 17,797,000 1,335,000 
      due from anti-cd20 therapeutic programs
    		-16,000,000 -66,200,000 70,400,000 -12,200,000 -800,000 -55,800,000 40,700,000 -7,700,000 9,800,000 -44,300,000 37,600,000 -16,000,000 20,600,000 -46,500,000 22,900,000 -12,300,000 22,200,000 -52,500,000 43,800,000 113,700,000 -86,100,000 70,500,000 78,600,000                                              
      inventory
    		-7,400,000 -89,900,000 62,000,000 -66,400,000 -19,200,000 -110,500,000 -77,700,000 -96,000,000 30,200,000 -93,000,000 27,900,000 18,100,000 -95,000,000 -100,700,000 -142,600,000 -139,800,000 -128,800,000 -81,300,000 -112,500,000 -45,700,000 -82,400,000 -126,000,000 -62,200,000 -66,500,000 -61,400,000 -20,300,000 129,000,000 -20,200,000 8,200,000 -42,700,000 2,600,000 75,800,000 -85,000,000 -39,100,000 -46,200,000 -10,500,000 -26,800,000 -39,700,000 -88,600,000 -24,013,000 -69,093,000 -59,787,000 -21,507,000 -55,709,000 -16,980,000 -53,643,000 -68,362,000 -60,809,000    -4,543,311 -19,828,000 -6,189,000 -21,843,000 -6,344,000 -12,326,000 -18,785,000 -28,890,000 -23,191,000 -13,664,000 605,000 -8,071,000 -15,507,000 21,748,000 -4,268,000 -19,763,000 -30,449,000 
      accrued expense and other current liabilities
    		286,000,000 -18,200,000 -300,500,000 108,800,000 31,400,000 61,500,000 -177,100,000 -495,500,000 421,000,000 167,900,000 -295,000,000 -745,700,000 -1,700,000 1,095,600,000 -461,600,000 147,900,000 -54,900,000 95,200,000 -283,600,000                                                  
      income tax assets and liabilities
    		-229,400,000 -603,800,000 69,100,000 16,400,000 69,800,000 -5,500,000 -2,200,000 -184,200,000 -32,400,000 -147,400,000 65,000,000 -42,100,000 -34,300,000 -167,800,000 101,900,000 -29,700,000 89,000,000 106,700,000 64,800,000 -82,800,000 -489,300,000 281,600,000 223,000,000 -48,500,000 -242,300,000 136,600,000 170,300,000 6,100,000 132,200,000 -74,200,000 257,600,000 1,133,400,000 285,200,000 80,400,000 -195,100,000                                  
      other changes in operating assets and liabilities
    		-104,400,000 -22,000,000 -53,500,000 -113,000,000 37,300,000 -46,900,000 -56,100,000 -2,500,000 -15,900,000 41,300,000 -96,800,000 -107,900,000 149,900,000 79,600,000 -213,600,000 -56,900,000 9,700,000 -16,400,000 -80,900,000 -40,100,000 -106,900,000 -8,600,000 18,500,000  19,300,000 90,800,000 -171,100,000  -89,700,000 28,700,000 -20,000,000  -62,900,000 -153,000,000 -34,300,000  12,000,000 35,300,000 14,800,000  -55,285,000 3,337,000 -69,711,000 31,407,000 -75,338,000 129,402,000 33,654,000 35,212,000 38,262,000 -50,615,000 -20,036,000                  
      net cash flow provided by operating activities
    		1,272,500,000 160,900,000 259,300,000 760,900,000 935,600,000 625,800,000 553,200,000 12,500,000 592,400,000 487,000,000 455,300,000 -175,000,000 661,000,000 736,500,000 161,800,000 838,300,000 805,300,000 1,227,300,000 769,000,000                                                  
      cash flow from investing activities:
    		                                                                    
      purchases of property, plant and equipment
    		-46,200,000 -26,600,000 -37,100,000 -39,300,000 -35,000,000 -33,500,000 -45,900,000 -65,200,000 -74,200,000 -71,000,000 -66,600,000 -86,400,000 -59,100,000 -36,900,000 -57,900,000 -51,600,000 -42,000,000 -71,900,000 -92,600,000 -86,000,000 -84,100,000 -105,000,000 -149,700,000 -110,400,000 -90,100,000 -186,900,000 -127,100,000 -225,900,000 -163,200,000 -186,800,000 -194,700,000 -230,600,000 -229,100,000 -197,700,000 -210,000,000 -182,100,000 -170,300,000 -136,800,000 -126,900,000 -186,115,000 -229,197,000 -129,858,000 -97,830,000 -64,002,000 -54,306,000 -80,188,000 -54,151,000 -33,289,000 -58,064,000 -72,896,000 -54,551,000 -172,930,780 -53,993,000 -64,868,000 -71,062,000 -86,031,000 -108,356,000 -58,502,000 -79,846,000 -37,402,000         
      purchases of marketable securities
    		       0 -1,020,400,000 -2,799,100,000 -1,321,200,000 -642,600,000 -494,300,000 -1,178,100,000 -1,133,500,000 -1,436,100,000 -745,700,000 -713,600,000 -913,300,000 -1,748,600,000 -895,200,000 -2,069,200,000 -1,684,700,000 -1,200,500,000 -1,977,000,000 -1,250,100,000 -825,000,000 -1,601,000,000 -1,319,500,000 -2,855,100,000 -1,919,200,000 -1,261,300,000 -1,557,900,000 -1,279,300,000 -1,256,700,000 -2,281,500,000 -1,798,400,000 -1,918,900,000 -1,914,400,000 -1,994,758,000 -2,825,096,000 -1,722,088,000 -322,958,000 -1,121,395,000 -666,211,000 -855,635,000 -457,294,000 -1,160,680,000 -938,409,000 -576,842,000 -677,092,000 -1,987,022,231 -1,362,768,000 -740,897,000 -628,500,000 -431,659,000 -743,726,000 -333,147,000 -989,821,000 -878,550,000 -352,644,000 -268,241,000       
      acquisition of hi-bio, net of cash acquired
    		   0                                                                 
      proceeds from sale of equity interest in samsung bioepis
    		   0 0   0 0   0                                                         
      proceeds from sale of priority review voucher
    		   0 -14,400,000                                                                
      acquisitions of intangible assets
    		-5,300,000 0 -10,000,000 -27,000,000 -95,000,000 -9,100,000 -75,000,000 0 -13,400,000 -16,000,000 -5,000,000 -1,000,000 0   -16,900,000    -15,000,000 0 0 -37,000,000     0 0   -65,000,000 -50,100,000 -5,100,000 -855,200,000 -1,200,000                                 
      proceeds from sales of strategic investments
    		   48,000,000 39,200,000 1,900,000 55,600,000 13,400,000 3,000,000 69,400,000 33,800,000     2,300,000 0 0 91,200,000 74,400,000 0 0 500,000 3,300,000 166,300,000                                            
      net cash flow provided by investing activities
    		-35,100,000 -57,000,000 -47,300,000 -18,600,000 -1,181,100,000 466,500,000 -66,000,000 -652,300,000 -1,742,200,000 -753,500,000 -953,000,000 -141,100,000 1,672,200,000 693,500,000 -648,000,000    -64,700,000                                                  
      cash flow from financing activities:
    		                                                                    
      payments related to issuance of stock for share-based compensation arrangements
    		5,200,000 6,100,000 -24,300,000 3,500,000 6,000,000 6,100,000 -46,900,000 3,700,000 6,600,000 5,500,000 -60,100,000 3,900,000 5,700,000 9,300,000 -20,800,000 7,600,000 5,900,000 12,900,000 -27,100,000 7,200,000 7,400,000 10,400,000 -29,600,000  6,700,000 8,600,000 -32,200,000 4,600,000 7,600,000 6,900,000 -21,200,000 5,400,000 7,100,000 7,700,000 -25,500,000                                  
      proceeds from borrowings
    		-300,000       0            100,000 0                   -436,000                 617,000            
      repayments of borrowings
    		0                                                    0 0 -12,474,000 -1,500,000,000 0            
      cash paid for contingent consideration
    		                                                                    
      net cash flow provided by financing activities
    		-130,200,000 -11,700,000 -23,000,000 7,900,000 -6,600,000 -245,200,000 -439,600,000 -646,100,000 848,600,000 -9,800,000 -43,400,000 -7,400,000 -1,251,900,000 -471,500,000 -16,500,000                                       134,828,000 -250,129,000 -787,532,000   64,412,000 24,401,000         
      net increase in cash and cash equivalents
    		1,107,200,000 92,200,000 189,000,000 750,200,000 -252,100,000 847,100,000 47,600,000 -1,285,900,000 -301,200,000 -276,300,000 -541,100,000 -323,500,000 1,081,300,000 958,500,000 -502,700,000 735,400,000 -174,800,000 510,100,000 -80,700,000 -934,600,000 -184,200,000 -197,600,000 -335,100,000 552,200,000 640,000,000 -522,500,000 1,019,000,000 -1,166,900,000 1,141,900,000 -2,840,700,000 2,535,100,000 40,700,000 362,000,000   273,700,000 722,200,000 246,300,000 -192,400,000 -2,765,537,000 2,813,095,000 -209,680,000 311,022,000 38,106,000 225,494,000 29,008,000 -271,792,000 96,456,000   -221,021,000 185,032,281 -390,304,000 547,551,000 -224,330,000 29,030,000   830,524,000 119,348,000 246,695,000 70,061,000 -191,368,000 -32,303,000 271,676,000 -341,908,000 361,957,000 66,996,000 
      effect of exchange rate changes on cash and cash equivalents
    		-3,200,000 68,300,000 34,300,000 -74,400,000 42,400,000 -12,600,000 -23,100,000 47,900,000 -28,700,000 -4,100,000 20,000,000 67,200,000 -52,300,000 -61,200,000 -9,400,000 -15,800,000 -25,400,000 14,400,000 -33,000,000 41,000,000 24,100,000 -8,800,000 12,700,000 17,600,000 -19,500,000 2,700,000 -400,000 4,800,000 -5,400,000 -17,100,000 -900,000 -15,000,000 16,600,000 29,900,000 7,900,000 -32,000,000 600,000 -15,000,000 15,100,000 -15,442,000 -6,170,000 13,707,000 -37,895,000 -3,510,000 545,000 6,296,000 997,000 -3,875,000 3,768,000 -6,353,000 4,618,000 -7,368,149 1,988,000 -3,343,000 2,324,000 -193,000 -542,000 -348,000 117,000 215,000 88,000        
      cash and cash equivalents, beginning of the period
    		0 0 2,375,000,000  0 0 1,049,900,000  0 0 3,419,300,000  0 0 2,261,400,000  0 0 1,331,200,000  0 0 2,913,700,000  0 0 1,224,600,000  0 0 1,573,800,000  0 0 2,326,500,000  0 0 1,308,000,000  0 0 1,204,924,000 0 602,562,000 0 0 570,721,000 0 0 514,542,000   0 0 659,662,000  0 0 661,377,000  0 0 568,168,000  0 0 209,447,000 
      cash and cash equivalents, end of the period
    		1,104,000,000 160,500,000 2,598,300,000  -209,700,000 834,500,000 1,074,400,000  -329,900,000 -280,400,000 2,898,200,000  1,029,000,000 897,300,000 1,749,300,000  -200,200,000 524,500,000 1,217,500,000  -160,100,000 -206,400,000 2,591,300,000  620,500,000 -519,800,000 2,243,200,000  1,136,500,000 -2,857,800,000 4,108,000,000  378,600,000 245,500,000 924,000,000  722,800,000 231,300,000 1,130,700,000  2,806,925,000 -195,973,000 1,478,051,000 34,596,000 828,601,000 35,304,000 -270,795,000 663,302,000 -5,088,000 158,672,000 298,139,000   544,208,000 -222,006,000 688,499,000  -1,174,255,000 830,641,000 780,940,000  69,490,000 -190,761,000 535,865,000  -341,908,000 361,957,000 276,443,000 
      repayment of borrowings
    		    0                0        0                                        
      (gain) loss on equity method investment
    		               -17,700,000                                                     
      gain on sale of equity interest in samsung bioepis
    		           0 0                                                        
      gain on sale of building
    		           0                                                         
      proceeds from sales and maturities of marketable securities
    		       0 5,698,600,000 1,275,500,000 406,700,000 566,300,000 1,643,200,000 917,900,000 543,600,000 1,377,300,000 575,400,000 633,500,000 819,200,000 2,058,700,000 1,360,800,000 1,490,600,000 2,389,300,000 2,139,400,000 611,800,000 1,766,600,000 1,489,200,000 1,179,000,000 1,192,000,000 2,733,800,000 4,068,900,000 1,093,300,000 888,100,000 1,700,200,000 1,884,300,000 2,193,100,000 2,362,200,000 1,642,500,000 1,181,100,000 699,626,000 2,387,857,000 601,954,000 373,563,000 560,013,000 757,512,000 620,511,000 75,201,000 4,329,506,000 489,450,000 599,497,000 824,434,000 2,666,203,637    917,972,000   1,606,127,000 803,675,000 319,042,000 445,040,000       
      acquisition of reata, net of cash acquired
    		       -590,500,000                                                             
      proceeds from sale of building
    		           0                                                         
      purchase of treasury stock
    		                                       -2,001,810,000 -2,955,997,000     -359,285,000 0 -41,023,000 -53,220,000 -446,780,000 -463,171,000  -179,171,000 0       0 -319,902,000    0 -154,115,000 -168,475,000 
      repayments of borrowings and premiums paid
    		                                                                    
      net (distribution) contribution to noncontrolling interest
    		       8,100,000 2,500,000 1,500,000 200,000 200,000 100,000 11,900,000 200,000                                                      
      cash and cash equivalents, beginning of the year
    		                                                                    
      cash and cash equivalents, end of the year
    		                                                                    
      amortization of inventory step-up
    		      44,100,000                                                              
      repayment of borrowings and premiums paid
    		      -400,000,000                                                              
      acquired in-process research and development
    		               0 0   0 0 0 75,000,000     0 27,500,000 75,000,000 10,000,000 240,000,000 0                           18,405,000         
      proceeds from divestiture of hillerød, denmark manufacturing operations
    		               0 0 0 28,100,000     0                                             
      (gain) loss on equity method investments
    		            0 -5,900,000 3,300,000                                                      
      purchases of treasury stock
    		            -250,000,000    -750,000,000 -450,000,000 -600,000,000  -1,250,000,000 -2,808,900,000 -2,220,200,000 -2,093,100,000 -717,900,000 -2,401,500,000 -655,800,000 -1,352,600,000 0 -2,750,000,000 -250,000,000 0 0 -781,800,000 -583,600,000                                  
      changes in operating assets and liabilities, net:
    		                                                                    
      (gain)/loss on divestiture of hillerød, denmark manufacturing operations
    		                                                                    
      purchase of sangamo therapeutics, inc. stock
    		                   0 0                                                
      purchase of denali therapeutics inc. stock
    		                   0                                                 
      purchase of sage therapeutics, inc. stock
    		                                                                    
      repayments of borrowings and premiums paid on debt exchange
    		                                                                    
      proceeds from sale of equity in samsung bioepis
    		                                                                    
      proceeds from the sales of strategic investments
    		                                                                    
      repayment of borrowings and premiums paid on debt exchange
    		                0 -700,000 -169,300,000                                                  
      contingent consideration paid related to fumapharm ag acquisition
    		                        0 0 -300,000,000  -300,000,000 -300,000,000 -600,000,000                                      
      acquisition of nightstar therapeutics plc, net of cash acquired
    		                       0 0                                            
      net cash flow used in financing activities
    		               9,800,000 -746,500,000 -564,500,000 -785,000,000                                                  
      net cash flow used in investing activities
    		                -233,600,000                                                    
      cash proceeds from settlement of swap
    		                                                                    
      net distribution to noncontrolling interest
    		                0        0   500,000 2,000,000                                        
      gain on interest rate swap
    		                                                                    
      loss on equity method investment
    		                 -34,300,000 18,200,000 -18,000,000                                                 
      depreciation, amortization and impairments
    		                  146,900,000  134,000,000 112,900,000 119,900,000 113,000,000 329,500,000 117,000,000 121,100,000                                          
      cash flows from operating activities:
    		                                                                    
      adjustments to reconcile net income to net cash flows from operating activities:
    		                                                                    
      (gain)/loss on divestiture of hillerod, denmark manufactuing operations
    		                                                                    
      unrealized (gain) loss on strategic investments
    		                   -723,600,000 81,500,000 -101,700,000 62,000,000  9,400,000 175,800,000 -375,000,000                                          
      accrued expenses and other current liabilities
    		                   -218,700,000 814,300,000 -94,000,000 -347,400,000 349,300,000 107,000,000 -77,700,000 -138,400,000 364,800,000 87,400,000 135,100,000 -121,800,000 277,100,000 -52,200,000 231,900,000 -684,200,000 793,300,000 -60,900,000 18,500,000 -180,800,000 248,732,000 -4,603,000 35,538,000 -205,467,000 141,069,000 -171,368,000   -180,910,000 52,102,000 134,004,000 -82,031,000 130,857,623 -6,970,000   65,682,000 8,895,000 24,258,000 -14,187,000 13,494,000 78,683,000 17,716,000 -22,635,000 -59,952,000 241,000 17,669,000 77,371,000 -7,727,000 
      net cash flows from operating activities
    		                   -367,100,000 1,181,100,000 1,948,500,000 1,467,300,000 1,960,200,000 1,694,900,000 1,964,000,000 1,459,500,000 1,895,400,000 1,735,900,000 1,099,300,000 1,457,100,000 1,518,300,000 1,628,300,000 1,169,200,000 235,200,000 1,576,600,000 986,600,000 995,800,000 963,400,000 1,040,395,000 895,448,000 1,047,220,000 733,037,000 990,593,000 104,626,000 671,922,000 625,212,000 178,939,000 541,784,000 635,581,000 194,625,000 1,623,479,383 409,292,000 512,193,000 276,022,000 366,985,000 345,862,000 210,426,000 202,018,000 262,329,000 241,805,000 259,838,000 183,372,000 156,253,000 274,740,000 173,095,000 228,782,000 212,886,000 
      cash flows from investing activities:
    		                                                                    
      purchase of ionis pharmaceuticals, inc. stock
    		                           0 800,000                                        
      proceeds from divesiture of hillerod, denmark manufacturing operations
    		                                                                    
      investment in samsung bioepis
    		                                                                    
      net cash flows from investing activities
    		                   -166,400,000 -52,400,000 -832,700,000 442,900,000   -110,800,000 238,800,000   -1,148,500,000 1,346,600,000            -502,771,000  5,993,000   155,941,000   618,000   -99,470,000 -250,223,000 449,577,000 -616,635,000     121,491,000 -385,374,000 -272,212,000 -70,944,000 -534,294,000 1,027,693,000 -4,714,000 
      cash flows from financing activities:
    		                                                                    
      net contribution (distribution) to noncontrolling interest
    		                                                                    
      contingent consideration payments
    		                                                                    
      net cash flows (used in) financing activities
    		                                                                    
      loss on divestiture of hillerød, denmark manufacturing operations
    		                       -40,200,000                                             
      net cash flows used in financing activities
    		                    -1,312,900,000 -1,313,400,000 -2,245,300,000 -2,116,400,000 -689,000,000 -2,375,700,000 -679,300,000 -1,437,000,000 25,100,000 -2,791,500,000 -268,600,000  -19,500,000 -751,000,000 -901,400,000           -318,522,000 -170,763,000 -238,424,000 -28,250,000 -417,440,000 -416,264,000 -1,782,908,155                 
      proceeds from settlement of net investment hedge
    		                                                                    
      other liabilities
    		                                                       9,957,000 13,652,000 26,437,000 -1,382,000 2,587,000         
      contingent consideration related to fumapharm ag acquisition
    		                               -300,000,000 -300,000,000 -300,000,000 -300,000,000 -300,000,000 -300,000,000 -300,000,000 -300,000,000 -300,000,000 -300,000,000 0 -250,000,000                          
      net contribution (distribution) to noncontrolling interests
    		                                                                    
      net cash contribution to bioverativ, inc.
    		                                                                    
      net cash flows used in investing activities
    		                           -1,625,300,000    -769,500,000 -1,246,800,000 -202,600,000 -744,200,000 -581,700,000 36,200,000 -736,100,000 -1,203,200,000 -1,807,529,000 -989,937,000     -324,392,000   -522,390,000           -167,382,000         
      loss on assets and liabilities held for sale
    		                         -2,300,000 115,500,000                                          
      other assets
    		                                                   -12,561,565 -21,187,000 32,325,000 -4,716,000 -2,711,000 71,495,000 -58,372,000 5,950,000 -18,835,000 -24,264,000 219,000       
      net cash contribution to bioverativ inc.
    		                                0                                    
      acquisitions of businesses, net of cash acquired
    		                                                                    
      net cash flows from financing activities
    		                                   -721,200,000 -300,600,000 -13,400,000 47,400,000 -1,998,403,000 2,907,584,000 -3,537,000 80,756,000  114,875,000                   83,656,000 67,880,000 19,291,000 -894,518,000 -141,176,000 
      depreciation, amortization and acquired in-process research and development
    		                                177,400,000                                    
      net cash contribution to bioverativ
    		                                  -302,700,000                                  
      net decrease in cash and cash equivalents
    		                                  -1,410,400,000              -8,856,000                    
      proceeds from issuance of stock for share-based compensation arrangements
    		                                   8,500,000 11,300,000 9,400,000 14,500,000 8,691,000 10,782,000 9,113,000 25,614,000 11,114,000 22,363,000 17,365,000 17,185,000 21,817,000 15,197,000 19,001,000 24,080,000 183,405,553                 
      excess tax benefit from share-based compensation
    		                                                   13,142,284                 
      changes in other tax assets and liabilities
    		                                                                    
      acquisitions of business, net of cash acquired
    		                                        0 0 -198,798,000 0 -25,000,000    0                    
      excess tax benefit from share-based awards
    		                                    2,900,000                                
      current taxes payable
    		                                     -376,800,000 225,100,000   -52,000,000 154,017,000                          
      excess tax benefit from stock options
    		                                      8,300,000  1,088,000 3,261,000 66,429,000 4,484,000 79,456,000        -566,000 -8,976,000 -10,822,000 -7,626,000 -38,266,000 -21,560,000 -4,647,000 -5,193,000         
      other long-term liabilities and taxes payable
    		                                                                    
      due from unconsolidated joint business
    		                                                   -28,642,171 -10,383,000 -12,321,000 -24,661,000 7,126,000 -5,414,000 1,196,000 -10,714,000 16,954,000 -11,389,000 7,543,000 -23,887,000 84,000 484,000 -598,000 -2,997,000 -497,000 
      acquisition of tysabri rights
    		                                             0                       
      acquisitions of businesses
    		                                                                    
      repayment of borrowings under senior notes
    		                                             0 -2,340,000 -450,000,000                     
      purchases of reverse repurchase agreements
    		                                               -2,968,000,000                     
      proceeds from borrowings under line of credit facility
    		                                               200,000,000                     
      acquisition of stromedix, inc., net of cash acquired
    		                                                  -72,401,000                  
      depreciation and amortization of property, plant and equipment, and intangible assets
    		                                                                    
      fair value adjustment of contingent consideration
    		                                                                    
      excess tax benefit from shared-based compensation
    		                                                                    
      write-down of inventory to net realizable value
    		                                                   11,798,082 7,378,000 12,634,000 5,452,000 4,386,000 2,020,000 4,745,000 8,117,000 6,717,000 381,000 559,000 8,751,000 3,298,000 18,333,000 16,102,000 8,308,000 41,304,000 
      impairment of marketable securities, investments and other assets
    		                                                   20,826,681                 
      non-cash interest income, foreign exchange remeasurement gain, net and other
    		                                                                    
      realized (gain) loss on sale of marketable securities and strategic investments
    		                                                                    
      other liabilities and taxes payable
    		                                                   17,650,436 54,291,000                
      acquisitions
    		                                                   -72,436,024                 
      acquisition of a variable interest entity
    		                                                   -84,867,048                 
      proceeds from the sale of property, plant and equipment
    		                                                                    
      purchases of intangible assets
    		                                                                    
      purchases of other investments
    		                                                   -4,486,501  -5,649,000 -2,390,000 -9,221,000  -3,704,000 -2,932,000 -12,886,000  -1,275,000 -2,211,000 -2,094,000     
      proceeds from the sale of strategic investments
    		                                                                    
      collateral received under securities lending
    		                                                    148,138,000 -31,173,000 -22,263,000 83,516,000             
      change in cash overdraft
    		                                                   11,778,414                 
      acquisition of noncontrolling interests
    		                                                                    
      net distributions to noncontrolling interests
    		                                                                    
      net proceeds from financing arrangement for the sale of the san diego facility
    		                                                                    
      repayments on financing arrangement for the sale of the san diego facility
    		                                                                    
      obligation under securities lending
    		                                                                    
      depreciation and amortization of property, plant and equipment and intangible assets
    		                                                   353,840,911                 
      realized gain on sale of marketable securities and strategic investments
    		                                                     9,702,000               
      (gain) loss on disposal of property, plant and equipment
    		                                                                    
      acquisition of noncontrolling interest
    		                                                                    
      proceeds from the issuance of stock for share-based compensation arrangements
    		                                                                    
      net contributions (to) from noncontrolling interests
    		                                                                    
      non-cash interest income and foreign exchange remeasurement gain
    		                                                   5,806,876                 
      net contributions from noncontrolling interests
    		                                                                    
      acquired in process research and development
    		                                                                    
      cash received upon termination of interest rate swap
    		                                                                    
      (gain) loss on sale of property, plant and equipment
    		                                                                    
      net cash flows from in investing activities
    		                                                                    
      loss on disposal of property, plant and equipment
    		                                                                    
      proceeds from the sale of a strategic equity investment
    		                                                                    
      net distributions to noncontrolling interest
    		                                                                    
      net contributions from noncontrolling interest
    		                                                                    
      non-cash interest income and foreign exchange remeasurement
    		                                                                    
      acquired in process research and development and license
    		                                                                    
      gain on sale of property, plant and equipment
    		                                                                    
      acquisitions, net of cash acquired
    		                                                    0 0 0 -25,000,000 -3,500,000 -50,000,000           
      proceeds from sale of property, plant and equipment
    		                                                        -143,000 16,742,000 0 70,000 38,274,000 85,000 2,006,000 33,851,000     
      repayments of long-term debt
    		                                                        0            
      net capital contribution from noncontrolling interest
    		                                                                    
      supplemental cash flow disclosures:
    		                                                                    
      cash paid during the year for:
    		                                                                    
      interest
    		                                                                    
      income taxes
    		                                                                    
      non-cash financing activity:
    		                                                                    
      conversion of subordinated notes to common and treasury stock
    		                                                                    
      collateral received under securities leading
    		                                                                    
      net income attributable to biogen idec inc.
    		                                                                    
      depreciation and amortization of fixed and intangible assets
    		                                                            87,217,000        
      noncontrolling interest in subsidiaries
    		                                                                    
      impairment of investments and other assets
    		                                                    30,142,000 16,051,000 6,559,000 8,892,000 18,279,000 653,000 3,053,000 2,460,000  582,000    17,536,000 0 14,588,000 
      changes in assets and liabilities, net:
    		                                                                    
      adjustments to reconcile net income to net cash flows from operating activities depreciation and amortization of fixed and intangible assets
    		                                                           88,815,000         
      minority interest in subsidiaries
    		                                                    1,773,000 1,013,000               
      gain on settlement of license agreements
    		                                                                    
      share based compensation
    		                                                                    
      non-cash interest income and foreign exchange translation gain
    		                                                                    
      facility impairments and (gain) loss on disposition
    		                                                                    
      proceeds from sale of product line
    		                                                                    
      purchase of other investments
    		                                                                    
      proceeds from issuance of stock for share based compensation arrangements
    		                                                    11,454,000 77,500,000 61,221,000 28,311,000 241,744,000            
      issuance of notes to fumedica
    		                                                                    
      adjustments to reconcile net income to net cash flows from operating activities depreciation and amortization of fixed & intangible assets
    		                                                       106,932,000             
      in-process research & development
    		                                                     0               
      non-cash interest expense
    		                                                     -23,439,000 4,009,000 8,142,000             
      proceeds from sales and maturities of marketable debt securities
    		                                                     743,116,000               
      proceeds from sale of property, plant, and equipment
    		                                                                    
      change in cash overdrafts
    		                                                     17,179,000 -12,517,000 13,390,000  -9,573,000 -645,000 3,000  -5,842,000 -12,967,000 7,664,000  -4,317,000 -8,511,000 -22,611,000 
      proceeds from borrowings, net of discounts and expenses
    		                                                     0 104,000 986,876,000             
      obligations under securities lending
    		                                                     31,173,000 22,263,000 -83,516,000             
      repayment of long-term debt
    		                                                                    
      adjustments to reconcile net income to net cash flows from operating activities
    		                                                                    
      depreciation and amortization of fixed & intangible assets
    		                                                                    
      accrued expenses and other liabilities
    		                                                                    
      repurchase of senior notes
    		                                                                -1,000 0   
      proceeds from line of credit
    		                                                                    
      in process research & development
    		                                                       25,000,000             
      minority interest of subsidiaries
    		                                                       2,710,000             
      realized (gain) loss on sale of marketable securities and strategic investment
    		                                                       -5,267,000  -10,668,000           
      purchase of common stock
    		                                                       -240,219,000             
      non-cash interest income
    		                                                        1,360,000            
      acquired in process research & development and license
    		                                                                    
      gain on settlement of license agreement
    		                                                             0       
      facility impairment and (gain) loss on sale
    		                                                                    
      proceeds from sale of amevive
    		                                                            0 0       
      acquired in process research & development
    		                                                                    
      stock-based compensation
    		                                                          29,859,000 29,560,000  36,434,000 42,005,000 23,620,000  2,836,000 8,778,000 7,851,000 
      facility impairment and (gain) loss on disposition
    		                                                                    
      proceeds from the sale of a strategic investment
    		                                                                    
      net cash flows from (used in) investing activities
    		                                                                    
      proceeds from issuance of stock for share based payment arrangements
    		                                                                    
      proceeds of loan from joint venture partner
    		                                                                    
      repayments of loan to joint venture partner
    		                                                          0 -3,703,000         
      non-cash financing transaction:
    		                                                                    
      see note 14 “indebtedness” and note 16 “tender offer” for a discussion of non-cash financing transactions that occurred during the six months ended june 30, 2007.
    		                                                                    
      non-cash interest expense and amortization of investment premium
    		                                                           437,000 898,000   -108,000 -7,547,000 1,718,000 8,257,000 16,753,000 
      realized loss on sale of marketable securities
    		                                                           245,000  662,000 954,000 804,000     
      gain on sale of long-lived assets
    		                                                                    
      acquisition of syntonix, net of cash acquired
    		                                                           -42,289,000         
      proceeds from issuance of stock for share-based payment arrangements
    		                                                           22,908,000         
      adjustments to reconcile net income to net cash flows from
    		                                                                    
      operating activities
    		                                                                    
      acquisition of in process research and development
    		                                                            0        
      (gain) loss on settlement of license agreements
    		                                                                    
      stock based compensation
    		                                                                    
      realized (gain) loss on investments and other
    		                                                                    
      impairment of property, plant and equipment
    		                                                                807,000 -3,156,000 0 6,223,000 
      impairment of investments
    		                                                               2,107,000     
      changes in, net of assets and liabilities acquired:
    		                                                                    
      other long-term liabilities
    		                                                            3,525,000 2,426,000 2,149,000 3,605,000 3,191,000 1,356,000 -5,339,000 7,639,000 
      acquisition of fumapharm, net of cash acquired
    		                                                                    
      acquisition of conforma, net of cash acquired
    		                                                                    
      issuance of stock for stock based compensation arrangements
    		                                                                    
      proceeds from joint venture partner
    		                                                                    
      repayments to joint venture partner
    		                                                                    
      facility impairments and (gain) loss on sale
    		                                                                    
      tax benefit from stock options
    		                                                             -2,052,000 4,954,000 -15,195,000 13,490,000 -5,694,000 1,131,000 16,438,000 
      deferred revenue
    		                                                             -15,456,000 189,000 2,298,000 -1,675,000 2,214,000 -4,389,000 7,083,000 
      payments for acquisition of fumapharm, net of cash acquired
    		                                                             0       
      payments for acquisition of conforma, net of cash acquired
    		                                                             0       
      acquisitions of property, plant and equipment
    		                                                             -54,118,000 -14,092,000 -65,630,000 -102,426,000 -59,734,000 -90,370,000 -65,846,000 
      issuance of treasury stock for stock-based compensation arrangements
    		                                                             12,351,000 18,131,000 56,356,000     
      loan proceeds from joint venture partner
    		                                                             73,000 10,790,000 4,441,000     
      cash paid during the period for tax liabilities
    		                                                             118,372,000       
      cash paid during the period for interest
    		                                                                    
      acquisition of in process research & development
    		                                                                    
      non-cash interest income and amortization of investment premium
    		                                                                    
      impact of inventory step-up related to inventory sold
    		                                                              919,000 4,002,000     
      facility impairments and loss on sale
    		                                                              -800,000 -298,000 15,208,000    
      effect of exchange rate changes on cash & cash equivalents
    		                                                                    
      cash flows from operating activities
    		                                                                    
      other current and other assets
    		                                                               -3,880,000 21,059,000 -4,427,000 835,000 14,758,000 
      cash flows from investing activities
    		                                                                    
      purchases of marketable securities available-for-sale
    		                                                               -596,216,000 -211,572,000 -626,988,000 -205,272,000 -290,452,000 
      proceeds from sales and maturities of marketable securities available-for-sale
    		                                                               357,877,000 245,659,000 260,093,000 921,543,000 354,839,000 
      cash flows from financing activities
    		                                                                    
      write-off of acquired in-process research and development
    		                                                                    
      realized gain on sale of marketable securities available-for-sale
    		                                                                   1,679,000 
      cash received from acquisition of biogen, inc., net of cash paid
    		                                                                    
      restricted cash
    		                                                                    
      proceeds from sale of manufacturing facility
    		                                                                0 0   
      issuance of common stock for option exercises and employee stock purchase plan
    		                                                                    
      issuance of treasury stock for option exercises and employee stock purchase plan
    		                                                                  14,523,000 49,910,000 
      change in cash overdraft.
    		                                                                    
      proceeds from loan
    		                                                                    
      supplemental cash flow data
    		                                                                    
      realized loss on sale of marketable securities available-for-sale
    		                                                                 1,678,000   
      impact of inventory step-up
    		                                                                 4,235,000 4,541,000 3,537,000 
      purchases of investments and other assets
    		                                                                 -107,665,000 -6,338,000 -3,255,000 
      issuance of common stock for stock-based compensation arrangements
    		                                                                    
      loss on sale of manufacturing facility
    		                                                                    
      increase in investments and other assets
    		                                                                    
      proceeds from issuance of notes payable
    		                                                                    
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.